Neurocrine (NBIX) Stock Forecast & Price Target

Compare

1,549 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NBIX Analyst Ratings

Strong Buy

15 Buy

3 Hold

0 Sell

Based on 18 analysts giving stock ratings to

Neurocrine

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NBIX Stock 12 Month Forecast

Average Price Target

$182.06

▲(35.98% Upside)

Based on 18 Wall Street analysts offering 12 month price targets for Neurocrine in the last 3 months. The average price target is $182.06 with a high forecast of $203.00 and a low forecast of $147.00. The average price target represents a 35.98% change from the last price of $133.89.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"105":"$105","204":"$204","129.75":"$129.8","154.5":"$154.5","179.25":"$179.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":203,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$203.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":182.06,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$182.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":147,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$147.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[105,129.75,154.5,179.25,204],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,141.83,146.53538461538463,151.24076923076925,155.94615384615386,160.65153846153848,165.3569230769231,170.0623076923077,174.7676923076923,179.47307692307692,184.17846153846153,188.88384615384615,193.58923076923077,198.29461538461538,{"y":203,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,141.83,144.9246153846154,148.01923076923077,151.11384615384617,154.20846153846153,157.30307692307693,160.39769230769232,163.4923076923077,166.58692307692309,169.68153846153848,172.77615384615385,175.87076923076924,178.9653846153846,{"y":182.06,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,141.83,142.2276923076923,142.62538461538463,143.02307692307693,143.42076923076925,143.81846153846155,144.21615384615384,144.61384615384617,145.01153846153846,145.40923076923076,145.80692307692308,146.20461538461538,146.6023076923077,{"y":147,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":136.5,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":151.82,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":118.72,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.59,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":124.56,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 63,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128.91,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":141.92,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":143.21,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 74,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":150.88,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 74,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":141.83,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 75,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$203.00

Average Price Target$182.06

Lowest Price Target$147.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

David Amsellem

Piper Sandler

$179

Buy

33.69%

Upside

Reiterated

01/28/26

Neurocrine (NBIX) Receives a Buy from Piper Sandler

Tazeen Ahmad

Bank of America Securities

$191

Buy

42.65%

Upside

Reiterated

01/27/26

Bank of America Securities Reaffirms Their Buy Rating on Neurocrine (NBIX)

Danielle Brill

Truist Financial

Buy

―

Reiterated

01/26/26

Analysts Offer Insights on Healthcare Companies: Caris Life Sciences, Inc. (NASDAQ: CAI), Madrigal Pharmaceuticals (NASDAQ: MDGL) and Neurocrine (NASDAQ: NBIX)

Sean Laaman

Morgan Stanley

$175

Hold

30.70%

Upside

Reiterated

01/26/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Apogee Therapeutics (NASDAQ: APGE) and Neurocrine (NASDAQ: NBIX)

Ashwani Verma

UBS

$188→$178

Buy

32.94%

Upside

Reiterated

01/23/26

UBS Reaffirms Their Buy Rating on Neurocrine (NBIX)

Anupam Rama

J.P. Morgan

$179→$177

Buy

32.20%

Upside

Reiterated

01/11/26

Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX) and Medline, Inc. Class A (NASDAQ: MDLN)

Myles Minter

William Blair

Buy

―

Reiterated

01/08/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Brian Abrahams

RBC Capital

$180

Buy

34.44%

Upside

Reiterated

01/08/26

Analysts Are Bullish on These Healthcare Stocks: SOPHiA GENETICS (SOPH), Verastem (VSTM)

Sumant Kulkarni

Canaccord Genuity

$164

Buy

22.49%

Upside

Reiterated

12/19/25

Neurocrine (NBIX) Receives a Buy from Canaccord Genuity

Andrew Fein

H.C. Wainwright

$168→$198

Buy

47.88%

Upside

Reiterated

12/17/25

Neurocrine's Strategic Growth and Innovation: Analyst Upgrades Price Target to $198 with Buy Rating

Ami Fadia

Needham

$184

Buy

37.43%

Upside

Reiterated

12/17/25

Neurocrine's Strategic Pipeline Positions for Growth in Addressing Unmet Medical Needs

Cory Kasimov

Evercore ISI

$200

Buy

49.38%

Upside

Reiterated

12/17/25

Evercore ISI Sticks to Their Buy Rating for Neurocrine (NBIX)

Akash Tewari

Jefferies

$174

Buy

29.96%

Upside

Reiterated

12/17/25

Jefferies Keeps Their Buy Rating on Neurocrine (NBIX)

Yigal Nochomovitz

Citi

$203

Buy

51.62%

Upside

Reiterated

12/16/25

Neurocrine Biosciences: Driving Innovation with Ambitious R&D Goals and Promising Pipeline Advancements

Uy Ear

Mizuho Securities

$146→$175

Hold

30.70%

Upside

Reiterated

12/12/25

Mizuho Securities Reaffirms Their Hold Rating on Neurocrine (NBIX)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

David Amsellem

Piper Sandler

$179

Buy

33.69%

Upside

Reiterated

01/28/26

Neurocrine (NBIX) Receives a Buy from Piper Sandler

Tazeen Ahmad

Bank of America Securities

$191

Buy

42.65%

Upside

Reiterated

01/27/26

Bank of America Securities Reaffirms Their Buy Rating on Neurocrine (NBIX)

Danielle Brill

Truist Financial

Buy

―

Reiterated

01/26/26

Analysts Offer Insights on Healthcare Companies: Caris Life Sciences, Inc. (NASDAQ: CAI), Madrigal Pharmaceuticals (NASDAQ: MDGL) and Neurocrine (NASDAQ: NBIX)

Sean Laaman

Morgan Stanley

$175

Hold

30.70%

Upside

Reiterated

01/26/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Apogee Therapeutics (NASDAQ: APGE) and Neurocrine (NASDAQ: NBIX)

Ashwani Verma

UBS

$188→$178

Buy

32.94%

Upside

Reiterated

01/23/26

UBS Reaffirms Their Buy Rating on Neurocrine (NBIX)

Anupam Rama

J.P. Morgan

$179→$177

Buy

32.20%

Upside

Reiterated

01/11/26

Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX) and Medline, Inc. Class A (NASDAQ: MDLN)

Myles Minter

William Blair

Buy

―

Reiterated

01/08/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Brian Abrahams

RBC Capital

$180

Buy

34.44%

Upside

Reiterated

01/08/26

Analysts Are Bullish on These Healthcare Stocks: SOPHiA GENETICS (SOPH), Verastem (VSTM)

Sumant Kulkarni

Canaccord Genuity

$164

Buy

22.49%

Upside

Reiterated

12/19/25

Neurocrine (NBIX) Receives a Buy from Canaccord Genuity

Andrew Fein

H.C. Wainwright

$168→$198

Buy

47.88%

Upside

Reiterated

12/17/25

Neurocrine's Strategic Growth and Innovation: Analyst Upgrades Price Target to $198 with Buy Rating

Ami Fadia

Needham

$184

Buy

37.43%

Upside

Reiterated

12/17/25

Neurocrine's Strategic Pipeline Positions for Growth in Addressing Unmet Medical Needs

Cory Kasimov

Evercore ISI

$200

Buy

49.38%

Upside

Reiterated

12/17/25

Evercore ISI Sticks to Their Buy Rating for Neurocrine (NBIX)

Akash Tewari

Jefferies

$174

Buy

29.96%

Upside

Reiterated

12/17/25

Jefferies Keeps Their Buy Rating on Neurocrine (NBIX)

Yigal Nochomovitz

Citi

$203

Buy

51.62%

Upside

Reiterated

12/16/25

Neurocrine Biosciences: Driving Innovation with Ambitious R&D Goals and Promising Pipeline Advancements

Uy Ear

Mizuho Securities

$146→$175

Hold

30.70%

Upside

Reiterated

12/12/25

Mizuho Securities Reaffirms Their Hold Rating on Neurocrine (NBIX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Neurocrine

3 Months

xxx

Success Rate

12/18 ratings generated profit

Average Return

+4.34%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +4.34% per trade.

1 Year

Laura ChicoWedbush

Success Rate

13/20 ratings generated profit

Average Return

+3.21%

reiterated a buy rating 4 months ago

Copying Laura Chico's trades and holding each position for 1 Year would result in 65.00% of your transactions generating a profit, with an average return of +3.21% per trade.

2 Years

xxx

Success Rate

27/41 ratings generated profit

Average Return

+26.08%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 65.85% of your transactions generating a profit, with an average return of +26.08% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NBIX Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NBIX has received 75 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. NBIX average Analyst price target in the past 3 months is 182.06.

Each month's total comprises the sum of three months' worth of ratings.

NBIX Financial Forecast

NBIX Earnings Forecast

Next quarter’s earnings estimate for NBIX is $1.84 with a range of $1.34 to $2.44. The previous quarter’s EPS was $2.04. NBIX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.25% of the time in the same period. In the last calendar year NBIX has Performed in-line its overall industry.

NBIX Sales Forecast

Next quarter’s sales forecast for NBIX is $796.33M with a range of $760.80M to $829.11M. The previous quarter’s sales results were $794.90M. NBIX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.18% of the time in the same period. In the last calendar year NBIX has Performed in-line its overall industry.

NBIX Stock Forecast FAQ

What is NBIX’s average 12-month price target, according to analysts?

Based on analyst ratings, Neurocrine’s 12-month average price target is 182.06.

What is NBIX’s upside potential, based on the analysts’ average price target?

Neurocrine has 35.98% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is NBIX a Buy, Sell or Hold?

Neurocrine has a consensus rating of Strong Buy which is based on 15 buy ratings, 3 hold ratings and 0 sell ratings.

What is Neurocrine’s price target?

The average price target for Neurocrine is 182.06. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $203.00 ,the lowest forecast is $147.00. The average price target represents 35.98% Increase from the current price of $133.89.

What do analysts say about Neurocrine?

Neurocrine’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Streets Analysts.

How can I buy shares of NBIX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Neurocrine (NBIX) Stock Forecast & Price Target

NBIX Analyst Ratings

NBIX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Neurocrine

NBIX Analyst Recommendation Trends

NBIX Financial Forecast

NBIX Earnings Forecast

NBIX Sales Forecast

NBIX Stock Forecast FAQ

Detailed List of Analyst Forecasts